資源描述:
《術(shù)前小劑量奧曲肽在預(yù)防ercp術(shù)后胰腺炎和高淀粉酶血癥中的應(yīng)用研究》由會(huì)員上傳分享,免費(fèi)在線閱讀,更多相關(guān)內(nèi)容在學(xué)術(shù)論文-天天文庫。
1、授予單位代碼10089學(xué)號(hào)或申請?zhí)?3282HebeiMedicalUniversity碩士學(xué)位論文在職科學(xué)學(xué)位術(shù)前小劑量奧曲肽在預(yù)防ERCP術(shù)后胰腺炎和高淀粉酶血癥中的應(yīng)用研究學(xué)位申請人:王菲導(dǎo)師:劉科霞教授專業(yè):外科學(xué)二級學(xué)院:滄州市中心醫(yī)院2015年3月河北醫(yī)科大學(xué)學(xué)位論文使用授權(quán)及知識(shí)產(chǎn)權(quán)歸屬承諾本學(xué)位論文在導(dǎo)師(或指導(dǎo)小組)的指導(dǎo)下,由本人獨(dú)立完成。本學(xué)位論文研究所獲得的研究成果,其知識(shí)產(chǎn)權(quán)歸河北醫(yī)科大學(xué)所有《>河北醫(yī)科大學(xué)有權(quán)對本學(xué)位論文進(jìn)行交流、公開和使用。凡發(fā)表與學(xué)位論文主要內(nèi)容相關(guān)的論文,第一署名為單位河北醫(yī)科大學(xué),
2、試驗(yàn)材料、原始數(shù)據(jù)、申報(bào)的專利等知識(shí)產(chǎn)權(quán)均歸河北醫(yī)科大學(xué)所有。否則,承擔(dān)相應(yīng)法律責(zé)任。、、/務(wù)1V'研究生簽名:_導(dǎo)師簽章力
3、^(減N??曰河北醫(yī)科大學(xué)研究生學(xué)位論文獨(dú)創(chuàng)性聲明本論文是在導(dǎo)師指導(dǎo)下進(jìn)行的研究工作及取得的研究成果,除了文中特別加以標(biāo)注和致謝等內(nèi)容外,文中不包含其他人已經(jīng)發(fā)表或撰寫的研究成果,指導(dǎo)教師對此進(jìn)行了審定。$論文由本人獨(dú)立撰寫,文責(zé)自負(fù)。、研究生簽名:*導(dǎo)師簽章:&年劣月乂日目錄中文摘要·······························································
4、··············1英文摘要·············································································3英文縮寫·············································································6研究論文術(shù)前小劑量奧曲肽在預(yù)防ERCP術(shù)后胰腺炎和高淀粉酶血癥中的應(yīng)用研究前言····················································
5、·························7材料與方法····································································8結(jié)果·············································································10附表·············································································14討論······
6、·······································································22結(jié)論·············································································27參考文獻(xiàn)·······································································27綜述經(jīng)內(nèi)鏡逆行性胰膽管造影術(shù)后胰腺炎的預(yù)防現(xiàn)狀················
7、·30致謝···················································································40個(gè)人簡歷·············································································41中文摘要術(shù)前小劑量奧曲肽在預(yù)防ERCP術(shù)后胰腺炎和高淀粉酶血癥中的應(yīng)用研究摘要目的:觀察術(shù)前應(yīng)用小劑量奧曲肽預(yù)防經(jīng)內(nèi)鏡逆行胰膽管造影術(shù)(endoscopicretrogradecholangio
8、pancreatography,ERCP)術(shù)后胰腺炎(Post-ERCPPancreatitis,PEP)和高淀粉酶血癥的療效,評價(jià)小劑量奧曲肽在ERCP術(shù)前應(yīng)用的臨床價(jià)值,為臨床ERCP術(shù)前預(yù)防性用藥提供依據(jù)。方法:制定嚴(yán)格的納入與排除標(biāo)準(zhǔn),收集自2011年8月至2014年12月期間在滄州市中心醫(yī)院普外科行ERCP治療且符合條件的553例患者資料為研究對象,包括男性308例,女性245例,年齡31~88(67.5±11.5)歲,其中膽管結(jié)石280例,膽管癌126例,胰頭癌89例,壺腹癌31例,十二指腸乳頭癌23例,十二指腸乳頭炎性狹
9、窄4例。記錄所有患者術(shù)前1d、術(shù)后6h、24h血清淀粉酶,術(shù)后患者有無腹痛、惡心嘔吐、發(fā)熱、上腹部壓痛等臨床表現(xiàn),確診為PEP的患者通過CT檢查結(jié)果判斷輕重程度。根據(jù)術(shù)前0.5h是否應(yīng)用小劑量奧曲肽(0.1mg)將研究對